T-Fovir A 25 mg (Tablet)
Unit Price: ৳ 90.00 (1 x 10: ৳ 900.00)
Strip Price: ৳ 900.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Tenofovir alafenamide |
| Company | Drug international ltd |
Indications
- Treatment of chronic hepatitis B virus infection in adults with compensated liver disease
Pharmacology
- Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor
- Phosphonamidate prodrug of tenofovir
- Cell-permeant compound enters hepatocytes by diffusion
- Converted to tenofovir through hydrolysis
- Phosphorylated to tenofovir diphosphate
- Inhibits HBV replication through incorporation into viral DNA
- Weak inhibitor of mammalian DNA polymerases
- No evidence of toxicity to mitochondria
Dosage & Administration
- Recommended dosage is 25 mg once daily with food in adults
- No dosage adjustment in renal impairment (except ESRD) and mild hepatic impairment
- Not recommended in decompensated hepatic impairment, pediatric use, and non-chronic hemodialysis ESRD
- Safety and efficacy not established in pediatric patients below 18 years and no significant differences observed in elderly subjects
Interaction
- Substrate of P-glycoprotein (P-gp) and BCRP
- Drugs affecting P-gp and BCRP activity may alter absorption
- Coadministration with drugs that inhibit P-gp and BCRP may increase absorption and plasma concentration
- Interactions with drugs affecting renal function may increase tenofovir concentrations
Side Effects
- Headache
- Stomach pain
- Tiredness
- Cough
- Nausea
- Back pain
- Lactic Acidosis/Severe Hepatomegaly with Steatosis
- Severe Acute Exacerbation of Hepatitis B
- New Onset or Worsening of Renal Impairment
Pregnancy & Lactation
- Prevalence of birth defects in live births following exposure to TAF-containing regimens
- Effect on human milk production or breastfed infant unknown
- Consider benefits of breastfeeding along with the mother’s clinical need for Tenofovir alafenamide
Precautions & Warnings
- Severe Acute Exacerbation of Hepatitis B after Discontinuation of Treatment
- Risk of Development of HIV-1 Resistance in Coinfected Patients
- New Onset or Worsening Renal Impairment
- Lactic Acidosis/Severe Hepatomegaly with Steatosis
Overdose Effects
- Monitor patient for toxicity if overdose occurs
- Treatment consists of general supportive measures
- Efficiently removed by hemodialysis
Therapeutic Class
- Hepatic viral infections (Hepatitis B)
Storage Conditions
- Store below 30°C
- Keep in original container
- Protect from light
- Keep out of children’s reach